General Biologicals Corporation (4117.TWO)
TWD 12.75
(-24.33%)
TWD 12.75
(-24.33%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 225.68 Million | 225 Million | 38.97 Million | 46.74 Million | -1.75 Million |
| Net Income | -187.71 Million | -46.12 Million | 38.6 Million | 48.29 Million | -39.04 Million |
| Depreciation & Amortization | 36.67 Million | 35.91 Million | 35.73 Million | 30.91 Million | 26.39 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | 21.02 Million | 513 Thousand |
| Change in working capital | 373.67 Million | 228.19 Million | -15.75 Million | -74.25 Million | 8.58 Million |
| Other non-cash items | 9.37 Million | 15.69 Million | 10.51 Million | 3.13 Million | 1.8 Million |
| Investing Cash Flow | -342.3 Million | -277.9 Million | -75.75 Million | -186.29 Million | 1.95 Million |
| Investments in PPE | -425.01 Million | -248.6 Million | -124.82 Million | -25.92 Million | -1.14 Million |
| Acquisitions | - | - | - | -29.5 Million | - |
| Investment purchases | 88.89 Million | -29.65 Million | 59.03 Million | -126.95 Million | - |
| Sales/Maturities of investments | 88.89 Million | - | - | - | - |
| Other Investing Activities | -6.18 Million | -1.84 Million | -11.48 Million | -5.16 Million | 3.1 Million |
| Financing Cash Flow | 72.37 Million | -9.73 Million | -4.26 Million | 471.79 Million | -14.2 Million |
| Debt repayment | -78.42 Million | -1.75 Million | -54 Thousand | -51.52 Million | -19.33 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 530 Million | 9.12 Million |
| Other Financing Activities | 50 Million | 5 Million | - | 504 Million | 5.12 Million |
| Accounts receivables | 25.81 Million | -14.9 Million | 33.32 Million | -20.04 Million | 9.14 Million |
| Accounts payables | -787 Thousand | - | - | - | - |
| Inventory | 31.23 Million | -35.47 Million | -18.48 Million | -35.44 Million | 3.08 Million |
| Other working capital | 316.74 Million | 287.07 Million | -10.17 Million | -18.63 Million | -3.64 Million |
| Cash at beginning of period | 262.18 Million | 308.77 Million | 350.6 Million | 22.54 Million | 36.54 Million |
| Cash at end of period | 217.12 Million | 262.18 Million | 308.77 Million | 350.6 Million | 22.54 Million |
| Capital Expenditure | -425.01 Million | -248.6 Million | -124.82 Million | -25.92 Million | -1.14 Million |
| Effect of forex changes on cash | -812 Thousand | 16.04 Million | -790 Thousand | -4.17 Million | 5000.00 |
| Net cash flow / Change in cash | -45.06 Million | -46.59 Million | -41.83 Million | 328.06 Million | -14 Million |
| Free Cash Flow | -199.33 Million | -23.59 Million | -85.85 Million | 20.81 Million | -2.9 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -53 Million | -53 Million | -51.64 Million | -187.71 Million | -51.64 Million | -47.77 Million |
| Depreciation & Amortization | 9.29 Million | 9.29 Million | 10.06 Million | 36.67 Million | 10.06 Million | 7.95 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.35 Million | - | - | - | - | - |
| Change in working capital | 6.09 Million | 6.09 Million | 76.95 Million | 373.67 Million | 76.95 Million | 109.94 Million |
| Other non-cash items | 22.14 Million | 23.49 Million | 2.8 Million | 9.37 Million | 2.8 Million | 4.53 Million |
| Investing Cash Flow | -627.76 Million | -627.76 Million | -53.78 Million | -342.3 Million | -53.78 Million | -117.37 Million |
| Investments in PPE | -627.18 Million | -627.18 Million | -65.4 Million | -425.01 Million | -65.4 Million | -146.6 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | 88.89 Million | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -579.5 Thousand | -579.5 Thousand | 11.62 Million | -6.18 Million | 11.62 Million | 29.23 Million |
| Financing Cash Flow | 648.37 Million | 648.37 Million | 37.59 Million | 72.37 Million | 37.59 Million | -1.41 Million |
| Debt repayment | - | - | - | -78.42 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 648.37 Million | 648.37 Million | 37.59 Million | 50 Million | 37.59 Million | -1.41 Million |
| Accounts receivables | -11.12 Million | -11.12 Million | 6.56 Million | 25.81 Million | 6.56 Million | 6.33 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -9.6 Million | -9.6 Million | 2.02 Million | 31.23 Million | 2.02 Million | 13.59 Million |
| Other working capital | 26.81 Million | 26.81 Million | 68.36 Million | 316.74 Million | 68.36 Million | 90 Million |
| Cash at beginning of period | - | - | - | 262.18 Million | - | - |
| Cash at end of period | -229 Thousand | -229 Thousand | 21.16 Million | 217.12 Million | 21.16 Million | -43.69 Million |
| Capital Expenditure | -627.18 Million | -627.18 Million | -65.4 Million | -425.01 Million | -65.4 Million | -146.6 Million |
| Effect of forex changes on cash | -6.7 Million | -6.7 Million | -833 Thousand | -812 Thousand | -833 Thousand | 427 Thousand |
| Net cash flow / Change in cash | -229 Thousand | -229 Thousand | 21.16 Million | -45.06 Million | 21.16 Million | -43.69 Million |
| Free Cash Flow | -641.32 Million | -641.32 Million | -27.22 Million | -199.33 Million | -27.22 Million | -71.94 Million |
RCGCF
KRAS
PGCMF
GNSMF
002164
001319